has yet to be determined, but could be related to on-treatment improvements in beta-cell or alpha-cell functions. 5, 6 Sodium-glucose cotransporter 2 (SGLT2) inhibitors inhibit sodium-glucose cotransport in the proximal tubule. This reduces the blood glucose level at which the capacity for glucose transport by SGLTs is saturated, and therefore, the blood glucose level at which glucose is spilled into the urine-also referred to as the renal threshold for glucose. 7 By lowering the renal threshold for glucose, glucose that would otherwise be reabsorbed in the kidney is excreted into the urine. The constitutive renal threshold for plasma glucose in patients with type 2 diabetes is typically in the range of ~10-11 mmol/L (180-200 mg/dL) without SGLT2 inhibitor treatment. 8 The amount of filtered glucose in the kidney is dependent on glomerular filtration rate (GFR) and blood glucose. Therefore, the amount of reabsorbed glucose increases linearly with blood glucose (for a given GFR) until the renal threshold for glucose is reached; with higher glucose levels, the reabsorbed glucose stays constant except for a minor splay between the two parts of the absorption curve. Empagliflozin is a potent and selective inhibitor of SGLT2. 
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| Study 1
Baseline patient characteristics were similar between the empagliflozin and sitagliptin groups (Table 1) . LS mean reductions 
| Study 2
Baseline patient characteristics were similar between the empagliflozin and glimepiride groups (Table 1) 
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(untreated) renal threshold for glucose, the greater the incremental excretion of glucose into the urine with SGLT2 inhibition, and
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